Biogen Schedules First Quarter 2001 Financial Results for April 12, 2001

Biogen, Inc. (NASDAQ: BGEN) will report its first quarter 2001 financial results on April 12, 2001, before market open.

Following the release of the financials, the Company will host a live webcast, where Biogen management will discuss the quarter, at 8:00 am (EST). The webcast can be accessed by going to the Investor Relations section on Biogen’s website ( Following the live webcast, an archived version of the call will be available at the same URL, until April 19, 2001.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products ( Prescribing Information ). Biogen’s research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at